rosiglitazone has been researched along with oxyntomodulin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Soni, H | 1 |
| Feng, Z; Wu, S; Xia, Z; Yang, X; Yi, G; Zheng, Y | 1 |
2 other study(ies) available for rosiglitazone and oxyntomodulin
| Article | Year |
|---|---|
Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity.
Topics: Animals; Clinical Trials as Topic; Diabetes Complications; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Mice; Mice, Obese; Obesity; Oxyntomodulin; Peptides; Rats; Receptors, Glucagon; Recombinant Proteins; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Venoms | 2016 |
Combination therapy with semaglutide and rosiglitazone as a synergistic treatment for diabetic retinopathy in rodent animals.
Topics: Animals; Antioxidants; Cell Line; Cell Survival; Diabetic Retinopathy; Disease Models, Animal; Drug Therapy, Combination; Ependymoglial Cells; Glial Fibrillary Acidic Protein; Glucagon-Like Peptides; Humans; Inflammation; Male; Phosphatidylinositol 3-Kinases; Protective Agents; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |